Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1 |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic neuroendocrine tumor |
| ICD-0-3 | C25 |
| Methods | Microarray, qPCR, Luciferase reporter assay etc. |
| Sample | pancreatic neuroendocrine tumors tissues, cell lines (MIN6 and MIN6-4N) |
| Expression Pattern | down-regulated |
| Function Description | We found that Meg3 has tumor-suppressor activity in PNET cells because the overexpression of Meg3 in MIN6 cells (insulin-secreting mouse PNET cell line) blocked cell proliferation and delayed cell cycle progression. Gene expression microarray analysis showed that Meg3 overexpression in MIN6 mouse insulinoma cells down-regulated the expression of the protooncogene c-Met (hepatocyte growth factor receptor), and these cells showed significantly reduced cell migration/invasion. Compared with normal islets, mouse or human MEN1-associated PNETs expressed less MEG3 and more c-MET |
| Pubmed ID | 25565142 |
| Year | 2015 |
| Title | Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for pancreatic neuroendocrine tumor | OMIM COSMIC |